Mastodon

Zetsyl (Capsules, Powder) Instructions for Use

ATC Code

J01CA01 (Ampicillin)

Active Substance

Ampicillin (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Broad-spectrum penicillin antibiotic, destroyed by penicillinase

Pharmacotherapeutic Group

Antibiotic, semi-synthetic penicillin

Pharmacological Action

A broad-spectrum antibiotic from the group of semi-synthetic penicillins. It exerts a bactericidal effect by inhibiting the synthesis of the bacterial cell wall.

It is active against aerobic gram-positive bacteria: Staphylococcus spp. (except for strains producing penicillinase), Streptococcus spp., Enterococcus spp., Listeria monocytogenes; aerobic gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Shigella spp., Salmonella spp., Bordetella pertussis, some strains of Haemophilus influenzae.

It is destroyed by bacterial β-lactamases.

Pharmacokinetics

After oral administration, it is well absorbed from the gastrointestinal tract. Ampicillin is distributed in most organs and tissues. It crosses the placental barrier and poorly penetrates the blood-brain barrier. In inflammation of the meninges, the permeability of the blood-brain barrier increases sharply. 30% of ampicillin is metabolized in the liver. It is excreted in the urine and bile.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to ampicillin: including infections of the ear, throat, nose, odontogenic infections, bronchopulmonary infections, acute and chronic infections of the genitourinary tract, gastrointestinal infections (including salmonellosis, cholecystitis), gynecological infections, meningitis, endocarditis, septicemia, sepsis, rheumatism, erysipelas, scarlet fever, infections of the skin and soft tissues.

ICD codes

ICD-10 code Indication
A02 Other salmonella infections
A38 Scarlet fever
A40 Streptococcal sepsis
A41 Other sepsis
A46 Erysipelas
G00 Bacterial meningitis, not elsewhere classified
H66 Suppurative and unspecified otitis media
H70 Mastoiditis and related conditions
I33 Acute and subacute endocarditis
J00 Acute nasopharyngitis (common cold)
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
K04 Diseases of pulp and periapical tissues (including periodontitis)
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
K83.0 Cholangitis
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L08.8 Other specified local infections of skin and subcutaneous tissue
M05 Seropositive rheumatoid arthritis
M79.0 Unspecified rheumatism
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N41 Inflammatory diseases of prostate
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
T79.3 Posttraumatic wound infection, not elsewhere classified
ICD-11 code Indication
1A09.Z Salmonella infection, unspecified
1B50 Scarlet fever
1B70.0Z Erysipelas, unspecified
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1B7Y Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1C44 Non-pyogenic bacterial infections of skin
1D01.0Z Bacterial meningitis, unspecified
1G40 Sepsis without septic shock
AA9Z Unspecified suppurative otitis media
AB11 Mastoiditis or related conditions
BB4Z Acute or subacute endocarditis, unspecified
CA00 Acute nasopharyngitis
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
DA09.Z Diseases of pulp and periapical tissues, unspecified
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DC13 Cholangitis
EA50.3 Staphylococcal scarlet fever
EB21 Pyoderma gangrenosum
FA20.0 Seropositive rheumatoid arthritis
FA27.2 Palindromic rheumatism
FB51.3 Fibroblastic rheumatism
FB56 Specified soft tissue diseases, not elsewhere classified
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA07.Z Salpingitis and oophoritis, unspecified
GA91.Z Inflammatory and other diseases of prostate, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
NF0A.3 Posttraumatic wound infection, not elsewhere classified
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Capsules, Powder

The dosage is set individually depending on the severity of the course, localization of the infection and the sensitivity of the pathogen.

For oral administration for adults, a single dose is 250-500 mg, the frequency of administration is 4 times/day. For children weighing up to 20 kg – 12.5-25 mg/kg every 6 hours.

For intramuscular, intravenous administration, a single dose for adults is 250-500 mg every 4-6 hours. For children, a single dose is 25-50 mg/kg.

The duration of treatment depends on the localization of the infection and the characteristics of the course of the disease.

The maximum daily dose for adults when taken orally is 4 g, with intravenous and intramuscular administration – 14 g.

Adverse Reactions

Allergic reactions urticaria, erythema, angioedema, rhinitis, conjunctivitis; rarely – fever, joint pain, eosinophilia; extremely rarely – anaphylactic shock.

From the digestive system nausea, vomiting.

Effects due to chemotherapeutic action oral candidiasis, vaginal candidiasis, intestinal dysbiosis, colitis caused by Clostridium difficile.

Contraindications

Infectious mononucleosis, lymphocytic leukemia, hypersensitivity to ampicillin and other penicillins, impaired liver function.

Use in Pregnancy and Lactation

Ampicillin can be used during pregnancy if indicated. Ampicillin is excreted in breast milk in low concentrations. If it is necessary to use ampicillin during lactation, the issue of stopping breastfeeding should be decided.

Use in Hepatic Impairment

Contraindicated in impaired liver function.

During treatment with ampicillin, systematic monitoring of liver function is necessary.

Use in Renal Impairment

Patients with impaired renal function require dose adjustment according to the creatinine clearance values.

During treatment with ampicillin, systematic monitoring of renal function is necessary. When used in high doses in patients with renal failure, a toxic effect on the central nervous system is possible.

Pediatric Use

Use is possible according to the dosage regimen.

Special Precautions

During treatment with ampicillin, systematic monitoring of kidney and liver function and the peripheral blood picture is necessary. Patients with impaired renal function require dose adjustment according to the creatinine clearance values.

When used in high doses in patients with renal failure, a toxic effect on the central nervous system is possible.

When using ampicillin in patients with bacteremia (sepsis), a bacteriolysis reaction (Jarisch-Herxheimer reaction) is possible.

Drug Interactions

Sulbactam, an irreversible β-lactamase inhibitor, prevents the hydrolysis and destruction of ampicillin by microbial β-lactamases.

With the simultaneous use of ampicillin with bactericidal antibiotics (including aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin), synergism is manifested; with bacteriostatic antibiotics (including macrolides, chloramphenicol, lincosamides, tetracyclines, sulfonamides) – antagonism.

Ampicillin enhances the effect of indirect anticoagulants by suppressing the intestinal microflora, reduces the synthesis of vitamin K and the prothrombin index.

Ampicillin reduces the effect of drugs in the metabolism of which PABA is formed.

Probenecid, diuretics, allopurinol, phenylbutazone, NSAIDs reduce the tubular secretion of ampicillin, which may be accompanied by an increase in its plasma concentration.

Antacids, glucosamine, laxatives, aminoglycosides slow down and reduce the absorption of ampicillin. Ascorbic acid increases the absorption of ampicillin.

Ampicillin reduces the effectiveness of oral contraceptives.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Aurobindo Pharma, Ltd. (India)

Dosage Form

Bottle Rx Icon Zetsyl Capsules 250 mg: 20 pcs.

Dosage Form, Packaging, and Composition

Capsules 1 caps.
Ampicillin (as trihydrate) 250 mg

10 pcs. – blister packs (2) – cardboard packs.

Marketing Authorization Holder

Aurobindo Pharma, Ltd. (India)

Dosage Form

Bottle Rx Icon Zetsyl Capsules 500 mg: 20 pcs.

Dosage Form, Packaging, and Composition

Capsules 1 caps.
Ampicillin (as trihydrate) 500 mg

10 pcs. – blister packs (2) – cardboard packs.

Marketing Authorization Holder

Aurobindo Pharma, Ltd. (India)

Dosage Form

Bottle Rx Icon Zetsyl Powder for solution for injection 500 mg: fl. 10 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for injection 1 fl.
Ampicillin (as sodium salt) 500 mg

Vials (1) – cardboard packs.

Marketing Authorization Holder

Aurobindo Pharma, Ltd. (India)

Dosage Form

Bottle Rx Icon Zetsyl Powder for solution for injection 1 g: fl. 10 pcs.

Dosage Form, Packaging, and Composition

Powder for solution for injection 1 fl.
Ampicillin (as sodium salt) 1 g

1 g – vials (1) – cardboard packs.

TABLE OF CONTENTS